Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciprofloxacin vs Cephalexin for Preventing Bladder Cancer Recurrence
NCT00003824Phase 3Terminated
- Sponsor
- SWOG Cancer Research Network
- Start
- Apr 1999
- Primary completion
- Jul 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ciprofloxacin in bladder cancer (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Recurrence-Free Survival at 5 years. Started Apr 1999; status: terminated.
02
Drugs
ciprofloxacin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00003824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003824.